CL2024002383A1 - Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas. - Google Patents
Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas.Info
- Publication number
- CL2024002383A1 CL2024002383A1 CL2024002383A CL2024002383A CL2024002383A1 CL 2024002383 A1 CL2024002383 A1 CL 2024002383A1 CL 2024002383 A CL2024002383 A CL 2024002383A CL 2024002383 A CL2024002383 A CL 2024002383A CL 2024002383 A1 CL2024002383 A1 CL 2024002383A1
- Authority
- CL
- Chile
- Prior art keywords
- tdp
- disease
- humanized anti
- binding molecules
- encephalopathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22157150 | 2022-02-16 | ||
| EP22177361 | 2022-06-06 | ||
| EP23152958 | 2023-01-23 | ||
| EP23153165 | 2023-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002383A1 true CL2024002383A1 (es) | 2025-01-03 |
Family
ID=85239102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002383A CL2024002383A1 (es) | 2022-02-16 | 2024-08-08 | Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250145695A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4479426A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507569A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240150774A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128540A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023221539A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243689A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002383A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20240378A (cg-RX-API-DMAC7.html) |
| IL (1) | IL315043A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009948A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202342519A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023156549A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11252156B2 (en) * | 2012-05-31 | 2022-02-15 | Ikonopedia, Inc. | Secure data transmission |
| AU2024341632A1 (en) * | 2023-09-15 | 2026-04-23 | Prothena Biosciences Limited | Compositions and methods of reducing immunogenicity and improving stability of antibodies |
| AU2024403128A1 (en) * | 2023-12-19 | 2026-06-25 | Vectory Therapeutics B.V. | Anti-tdp-43 antibodies and uses thereof |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| WO2025186332A1 (en) | 2024-03-05 | 2025-09-12 | Ac Immune Sa | Vectorized anti-tdp-43 antibodies |
| US20260069565A1 (en) * | 2024-09-12 | 2026-03-12 | Provectus Pharmatech, Inc. | Method of Treating Amyotrophic Lateral Sclerosis |
| KR20260044274A (ko) * | 2024-09-23 | 2026-04-02 | 주식회사 피플바이오 | Tdp-43에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2026132413A1 (en) | 2024-12-20 | 2026-06-25 | Bioarctic Ab | Antibody against tdp-43 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| JP4995423B2 (ja) | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008151055A1 (en) | 2007-06-01 | 2008-12-11 | Mayo Foundation For Medical Education And Research | Diagnosing neurodegenerative diseases |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CA2853412C (en) | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| EP2825197B1 (en) | 2012-03-16 | 2018-06-06 | Covagen AG | Novel binding molecules with antitumoral activity |
| CN114008073B (zh) | 2019-05-23 | 2025-08-12 | Ac免疫有限公司 | 抗tdp-43结合分子及其用途 |
| CN116615452A (zh) | 2020-08-14 | 2023-08-18 | Ac免疫有限公司 | 人源化抗tdp-43结合分子及其用途 |
-
2023
- 2023-02-16 AU AU2023221539A patent/AU2023221539A1/en active Pending
- 2023-02-16 CR CR20240378A patent/CR20240378A/es unknown
- 2023-02-16 TW TW112105586A patent/TW202342519A/zh unknown
- 2023-02-16 KR KR1020247029734A patent/KR20240150774A/ko active Pending
- 2023-02-16 CA CA3243689A patent/CA3243689A1/en active Pending
- 2023-02-16 EP EP23705273.3A patent/EP4479426A1/en active Pending
- 2023-02-16 US US18/837,534 patent/US20250145695A1/en active Pending
- 2023-02-16 AR ARP230100367A patent/AR128540A1/es unknown
- 2023-02-16 MX MX2024009948A patent/MX2024009948A/es unknown
- 2023-02-16 JP JP2024548410A patent/JP2025507569A/ja active Pending
- 2023-02-16 IL IL315043A patent/IL315043A/en unknown
- 2023-02-16 WO PCT/EP2023/053940 patent/WO2023156549A1/en not_active Ceased
-
2024
- 2024-08-08 CL CL2024002383A patent/CL2024002383A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250145695A1 (en) | 2025-05-08 |
| AR128540A1 (es) | 2024-05-22 |
| WO2023156549A1 (en) | 2023-08-24 |
| KR20240150774A (ko) | 2024-10-16 |
| AU2023221539A1 (en) | 2024-08-22 |
| CA3243689A1 (en) | 2023-08-24 |
| MX2024009948A (es) | 2024-08-22 |
| EP4479426A1 (en) | 2024-12-25 |
| TW202342519A (zh) | 2023-11-01 |
| IL315043A (en) | 2024-10-01 |
| CR20240378A (es) | 2024-10-03 |
| JP2025507569A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002125A1 (es) | Moléculas de unión anti-tdp-43 y uso de las mismas. | |
| MX2024009948A (es) | Moleculas de union anti-tdp-43 humanizadas y usos de las mismas. | |
| Zella et al. | Emerging immunotherapies for Parkinson disease | |
| Tian et al. | Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations | |
| SA520412379B1 (ar) | جزيئات رابطة مختلة الطي لبروتين ربط الحمض النووي دي أوكسي ريبوزي ذي الاستجابة التشابكية 43 كيلو دالتون | |
| Vasili et al. | Endogenous levels of alpha-synuclein modulate seeding and aggregation in cultured cells | |
| Neumann et al. | Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD–TDP subtypes | |
| MX2019000476A (es) | Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso. | |
| Dhillon et al. | A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies | |
| JO3711B1 (ar) | أجسام مضادة محددة لبروتين تاو وطرق استعمالها | |
| MX2021005323A (es) | Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn. | |
| Sebollela et al. | Elucidating molecular mass and shape of a neurotoxic Aβ oligomer | |
| Liu et al. | Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression | |
| JOP20220255A1 (ar) | أجسام tau المضادة لـ phf المضاد واستخداماتها | |
| Gold et al. | Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia | |
| MX2022016039A (es) | Anticuerpos anti-cd2. | |
| Wang et al. | HMGB1/Advanced Glycation End Products (RAGE) does not aggravate inflammation but promote endogenous neural stem cells differentiation in spinal cord injury | |
| Nakayama et al. | Identification of linear polyubiquitin chain immunoreactivity in tau pathology of Alzheimer’s disease | |
| Kanno et al. | Upregulation of the receptor-interacting protein 3 expression and involvement in neural tissue damage after spinal cord injury in mice | |
| MX2025003560A (es) | Nuevos compuestos para el diagnostico de las proteinopatias por proteina de union al acido desoxirribonucleico (adn) de respuesta transactiva de 43 kilodalton (tdp-43) | |
| BR112022025632A2 (pt) | Anticorpos anti-pd-1 e proteínas de fusão | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR118999A1 (es) | Moléculas de unión anti-tdp-43 y usos de las mismas | |
| EA202190601A1 (ru) | АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ | |
| Chen et al. | Remarkable increases of α1-antichymotrypsin in brain tissues of rodents during prion infection |